CAJ | 학술논문

目的：探讨p-gp170、GST-π和TopoⅡ在肝癌组织中的表达及临床意义。方法采取免疫组化法检测35例肝癌组织、20例癌旁组织和10例肝硬化组织中p-gp170、GST-π和TopoⅡ蛋白的表达，并对其与组织病理参数及生存率的关系进行分析。结果肝癌组织中的p-gp170、GST-π的阳性表达率均显著高于癌旁组织及肝硬化组织（P<0.05）。肝癌组织中TopoⅡ蛋白的表达与癌栓关系密切（P<0.05）。肝癌组织中p-gp170+GST-π的阳性表达率高于p-gp170+GST-π+TopoⅡ、p-gp170+TopoⅡ、GST-π+TopoⅡ的阳性表达率（P<0.05）。TopoⅡ阳性表达者的2 a生存率低于阴性表达者（P<0.05）。结论 p-gp170、GST-π在肝癌组织中的高表达，可作为肝癌组织恶变的标志物；TopoⅡ与肝癌的浸润转移及生存关系密切。
목적：탐토p-gp170、GST-π화TopoⅡ재간암조직중적표체급림상의의。방법채취면역조화법검측35례간암조직、20례암방조직화10례간경화조직중p-gp170、GST-π화TopoⅡ단백적표체，병대기여조직병리삼수급생존솔적관계진행분석。결과간암조직중적p-gp170、GST-π적양성표체솔균현저고우암방조직급간경화조직（P<0.05）。간암조직중TopoⅡ단백적표체여암전관계밀절（P<0.05）。간암조직중p-gp170+GST-π적양성표체솔고우p-gp170+GST-π+TopoⅡ、p-gp170+TopoⅡ、GST-π+TopoⅡ적양성표체솔（P<0.05）。TopoⅡ양성표체자적2 a생존솔저우음성표체자（P<0.05）。결론 p-gp170、GST-π재간암조직중적고표체，가작위간암조직악변적표지물；TopoⅡ여간암적침윤전이급생존관계밀절。
Objective To investigate the expressions and clinical significance of p-gp170,GST-πand TopoⅡin the hepatocellular carcinoma. Methods Immunohistochemical method was used to detect the expressions of p-gp170,GST-π and TopoⅡ in the 35 cases of hepatocellular carcinoma,the 20 cases of paraneoplastic tissues form hepatocellular carcinoma and the 10 cases of hepatic cirrhosis. The relationship with clinicopathologic parameters and survival rate were comprehensively analyzed. Results The positive expression rate of p-gp170,GST-π in the hepatocellular carcinoma were higher than those in the 20 cases of paraneoplastic tissues and the 10 cases of hepatic cirrhosis(P<0. 05). The expression of TopoⅡin the hepatocellular carcinoma was related with cancer embolus(P<0. 05). In the hepatocellular carcinoma,the positive expression rate of p-gp170+GST-πwas higher than those of the p-gp170+GST-π+TopoⅡ,the p-gp170+TopoⅡ,the GST-π+TopoⅡ(P<0. 05). The 2-year survival rate of the hepatocellular carcinoma with TopoⅡ positive expression was lower than that of the hepatocellular carcinoma with TopoⅡ negative expression(P<0. 05). Conclusion p-gp170,GST-π are higher expressions in the hepato-cellular carcinoma,and can be the marker of hepatocellular carcinoma;TopoⅡ may be relative to imbibition and survival of the hepatocellular carcinoma.